Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 3/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.35 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.35 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12686092 | 0.86 | FASN (0.38) | FASNGRIN1GRIN2AGRIN2DGRIN3B | |
| SCHEMBL12686166 | 0.85 | FASN (0.39) | FASNGRIN1GRIN2AGRIN2DGRIN3B | |
| SCHEMBL12686095 | 0.82 | EGLN1 (0.47) | EGLN1 | |
| SCHEMBL12686281 | 0.80 | PRKAG1 (0.52) | FASNGRIN1GRIN2AGRIN2DGRIN3B | |
| SCHEMBL12685947 | 0.77 | PRKAG1 (0.46) | FASNMAPTACHE | |
| SCHEMBL12686188 | 0.77 | PRKAG1 (0.44) | FASN | |
| SCHEMBL12686158 | 0.77 | GRIN2D (0.39) | FASNGRIN1GRIN2AGRIN2DGRIN3B | |
| SCHEMBL12686411 | 0.77 | GRIN2D (0.39) | FASNGRIN1GRIN2AGRIN2DGRIN3B | |
| SCHEMBL12686230 | 0.74 | GRIN2D (0.39) | FASNGRIN1GRIN2AGRIN2DGRIN3B | |
| SCHEMBL12686427 | 0.73 | GRIN2D (0.37) | FASNGRIN1GRIN2AGRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9855260-B2 | Quinolinone derivatives | GLAXOSMITHKLINE LLC (US) | 2018-01-02 | — | — | US | disclosed |
| US-9855260-B2 | Quinolinone derivatives | GLAXOSMITHKLINE LLC (US) | 2018-01-02 | — | — | US | disclosed |
| US-20150238480-A1 | QUINOLINONE DERIVATIVES | GLAXOSMITHKLINE LLC | 2015-08-27 | — | — | US | disclosed |
| US-20150238480-A1 | QUINOLINONE DERIVATIVES | GLAXOSMITHKLINE LLC | 2015-08-27 | — | — | US | disclosed |
| US-20150238480-A1 | QUINOLINONE DERIVATIVES | GLAXOSMITHKLINE LLC | 2015-08-27 | — | — | US | disclosed |
| US-9061998-B2 | Quinolinone derivatives | GLAXOSMITHKLINE LLC (US) | 2015-06-23 | — | — | US | disclosed |
| US-9061998-B2 | Quinolinone derivatives | GLAXOSMITHKLINE LLC (US) | 2015-06-23 | — | — | US | disclosed |
| WO-2012119978-A1 | QUINOLINONE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2012-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238480-A1 | QUINOLINONE DERIVATIVES | PRKAG2, PRKAB2, PRKAG1 | FASN 745/4885GRIN1 1700/4885GRIN2A 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.